BUSINESS ACQUISITION - Narrative (Details) - USD ($) $ in Thousands			3 Months Ended		6 Months Ended
	Apr. 04, 2017	Feb. 24, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	May 25, 2017
Business Acquisition [Line Items]
Realized loss on sale of short-term investment					$ 2,287	$ 0
Contingent consideration, payment made					(1,995)	251
Net income			$ 10,835	$ 12,755	17,230	$ 26,173
Interest Expense, Intangible Asset Amortization, and External Expenses Related to Acquisition [Member]
Business Acquisition [Line Items]
Net income					10,200
Derma Sciences | Interest Expense, Intangible Asset Amortization, and External Expenses Related to Acquisition [Member]
Business Acquisition [Line Items]
Net income					$ 2,900
Product Concentration Risk | BioD Morselized Amniotic Membrane Based Products
Business Acquisition [Line Items]
Percentage of revenue to product (less than)			1.00%		1.00%
TGX Medical
Business Acquisition [Line Items]
Consideration for acquisition	$ 5,300
Revenue of acquired company since acquisition			$ 200
Derma Sciences
Business Acquisition [Line Items]
Consideration for acquisition		$ 210,800
Revenue of acquired company since acquisition			23,800		$ 34,300
Payment of closing expenses		4,800
Settlement of stock compensation plan		4,300
Cash payment to former shareholders		$ 201,700
Preliminary purchase price allocation adjustment					1,700
Acquired deferred taxes			17,820		17,820
Deferred tax asset, federal net operating loss			39,700		39,700
Deferred tax asset, intangibles			15,800		15,800
Deferred tax asset, various			600		600
Deferred tax liabilities, intangibles			38,300		38,300
Deferred tax liabilities, adjustment to estimated fair value			1,500		1,500
Derma Sciences | BioD Earnout Payment
Business Acquisition [Line Items]
Revenue volatility percentage		13.50%
Fair value inputs, discount rate		3.00%
Contingent consideration range of outcomes, value, high		$ 26,500
Contingent consideration, liability		$ 9,100	7,000		7,000
Derma Sciences | Product Payment Contingent Consideration
Business Acquisition [Line Items]
Fair value inputs, discount rate		2.50%
Contingent consideration range of outcomes, value, high		$ 29,700
Contingent consideration, liability		$ 26,800					$ 26,600
Product payment rate		98.00%
Contingent consideration, payment made			900
Derma Sciences | Medihoney Earnout Payment
Business Acquisition [Line Items]
Revenue volatility percentage		27.50%
Fair value inputs, discount rate		4.50%
Contingent consideration range of outcomes, value, high		$ 5,000
Contingent consideration, liability		$ 1,300	$ 1,300		$ 1,300